Pfizer’s Ibrance is set to lose exclusivity in the US only by 2027, but the Indian market is buzzing with activity as generics including from top-ranked drug maker Sun Pharma vie for a share of the pie. Competing CDK4/6 inhibitors are already available but can cut-price palbociclib versions alter market dynamics?

Pfizer’s Ibrance is set to lose exclusivity in the US only by 2027, but the Indian market is buzzing with activity as generics including from top-ranked drug maker Sun Pharma vie for a share of the pie. Competing CDK4/6 inhibitors are already available but can cut-price palbociclib versions alter market dynamics?

Morphic said that Janssen had chosen to exit the partnership formed in 2019, just a little more than half a year after AbbVie did the same.

In a closely-watched case, the first of two planned in less than 18 months, MSN Laboratories scooped a mixed verdict from a US district court regarding its proposed generic version of Exelixis’ Cabometyx (cabozantinib) tyrosine kinase inhibitor.